Pharmastocks
PFIZER LTDPharma sector seems to be ending bearish trend
and might reverse towards bullish move.
Pfizer showing Morning star pattern which is
reversal bullish pattern on a daily time frame.
Pfizer is also taking support of 200 EMA which is
again a bullish sign.
Do your own analysis before buying trade.
BLISSGVS Long Idea...BLISSGVS is consolidating in monthly chart. Taking trade after monthly confirmation (close above resistance) is good for safe trader
Personally I'm following it in daily charts to get a good early entry with some risk.
Lets see how it turns.
NOTE: NO idea of comapny Fundamentals. Just a technical take. Should plan trade with proper risk management.
Alembic Pharma Swing Long Setup- Alembic Pharma is currently trading at 1242
- Alembic Pharma is compressing and I think it can shoot up more
- The Pharma Index has been outperforming for weeks and I think it still has a lot of upside to move up
- 1177 can be a very good zone to look for longs and if you are looking for swings
- Invalidation below 1120 manage risk
Short Term Trading idea in Dr. Lal Pathlabs, 17% upside possibleHello everyone, i hope you all will be doing good in your life and your trading as well. Today i have just brought a short term idea in Lab stocks. Stock name is Dr. Lal Pathlabs Ltd. and it is one of India’s leading consumer healthcare brand in diagnostic services. It has an integrated nationwide network, where patients and healthcare providers are offered a broad range of diagnostic and related healthcare tests and services for use in: core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions. The services of DLPL are aimed at individual patients, hospitals and other healthcare providers and corporates.
Stock has given near term consolidation breakout on daily and weekly time frame. Stock can travel towards all time high levels from here, I have already mention all the levels like stop loss and Targets. Stock is really good for long term investing as well. But for now i have just added kind of short term Idea. Please follow the levels.
Market Cap
₹ 29,198 Cr.
Current Price
₹ 3,494
High / Low
₹ 3,525 / 1,943
Stock P/E
76.5
Book Value
₹ 222
Dividend Yield
0.69 %
ROCE
25.2 %
ROE
20.4 %
Face Value
₹ 10.0
Industry PE
53.6
Debt
₹ 247 Cr.
EPS
₹ 45.7
Promoter holding
54.6 %
Intrinsic Value
₹ 743
Pledged percentage
0.00 %
EVEBITDA
40.4
Change in Prom Hold
0.00 %
Profit Var 5Yrs
12.4 %
Sales growth 5Years
13.1 %
Return over 5years
20.9 %
Debt to equity
0.13
Net profit
₹ 386 Cr.
ROE 5Yr
21.3 %
Profit growth
44.6 %
Earnings yield
1.97 %
PEG Ratio
6.15
Disclaimer:- Please always do your own analysis or consult with your financial advisor before taking any kind of trades.
Dear traders, If you like my work then do not forget to hit like and follow me, and guy's let me know what do you think about this idea in comment box, i would be love to reply all of you guy's.
Thankyou.
Piramal Pharma All Time High Breakout #PPLPHARMAKey Highlights : 👀
🔷 Name : NSE:PPLPHARMA
🔷 All Time High Breakout 🔥
🔷 Monthly Bollinger Bands Blast 🔥
Disclaimer: This is NOT investment advice. This post is meant for learning purposes only. Invest your capital at your own risk.
Happy Learning. Cheers!!
Shyorawat Arun Singh ❤️
(@Shyorawat_ArunSingh)
Founder : Shyorawat Investing School
DR. LAL PATH LABS LTD MASSIVE LONG OPPORTUNITYDr Lal Pathlabs Limited shown consolidation and correction and in charts
It can be seen in sorter time frame it has given rounding bottom break out.
Now after that if we see a longer time frame there is a big rounding bottom potential breakout happening it is also indicated by FII & DII holding increased by significant %
WOCKPHARMA: W pattern breakout may drive the price higher!
The 1700-1800 range has acted as a formidable barrier for this stock, with the price faced rejection at these levels on two separate occasions.
After experiencing a significant downturn, the price eventually found support around the 135 level, led the price to a period of consolidation.
During this time, the stock developed a Double Bottom pattern.
Following a substantial gap, it successfully broke out of the Double Bottom pattern with strong trading volume and is now positioned just above that breakout level.
At present, the stock is trading at nearly half its all-time high, making it an appealing option right now.
Thyrocare Technologies in Buying Zone with Strong Sales GrowthNSE:THYROCARE Thyrocare Technologies has shown a strong breakout after a long period of consolidation, supported by robust sales growth and consistent profitability. The stock is in a buying zone with strong volume, presenting a promising opportunity for investors.
Fundamentals:
Strong sales growth
Good dividend player
Consistent profitable growth
Technical:
Strong volume peak after consolidation, indicating potential buying interest
Stock is in a buying zone
May retest, so consider buying in small lots
Good liquidity
WANBURY LTD: 17-Year Resistance Shattered! Is This Pharma Stock WANBURY LTD: Breaking Resistance Like It's Going Out of Style!
Technical Analysis:
Breakout: Hold onto your hats, folks! Wanbury just smashed through a 17-year resistance level like a bull in a china shop... if the china shop had been reinforced for 17 years!
Trend: The stock is in a strong uptrend, climbing faster than a squirrel on an espresso-coated tree.
Volume: Huge volume activity observed. Traders are piling in like it's Black Friday at a discount pharmacy!
Candle Pattern: That breakout candle is so bullish, it's practically wearing horns and pawing the ground.
Support Levels: Previous resistance at 173.68 now likely to act as support. It's like the floor just became the ceiling, and Wanbury is redecorating the whole house!
Fundamental Factors:
Pharmaceutical sector seeing increased interest. Wanbury's producing more buzz than a beehive in a coffee shop.
Potential new product launches or regulatory approvals could be fueling the rally.
Risks:
After such a strong move, a pullback is possible. Even rockets need to refuel sometimes!
Keep an eye on broader market sentiment and sector-specific news.
Trade Idea:
Consider long positions with a stop loss below the breakout level. Target the psychological 200 level - it's time for Wanbury to join the 200 club!
Remember, traders, timing is everything. You don't want to be fashionably late to this 17-year breakout party!
Key Levels to Watch:
Resistance turned support: 173.68
Next psychological resistance: 200.00
Stop loss consideration: Below 170.00
Disclaimer: This analysis is for educational purposes only. Always do your own research and manage your risk. Remember, the stock market is like a rollercoaster - thrilling, but it helps to have a strong stomach and know when to exit!
Suven Pharma Breaks Out Like a Fever Dream"Suven Pharma Breaks Out Like a Fever Dream! 💊📈 #PharmaStocksGoBoom"
I. Current Price Action:
Price: ₹787.35
Change: +58.10 (+7.97%)
Volume: 3.673M (Higher than the number of pills in your grandma's medicine cabinet!)
II. Key Observations:
Breakout Bonanza: SUVENPHAR has busted through its long-term resistance faster than a hypochondriac racing to WebMD.
Side Channel Escape: The stock just broke out of its side channel, showing more excitement than a kid in a candy store (or should we say, pharmacy?).
Volume Surge: Trading volume is higher than the line at the doctor's office during flu season. This suggests strong conviction in the move.
Support Levels: The previous resistance around ₹760 could now act as support. If it holds, it'll be stronger than the taste of cough syrup.
III. Trading Idea:
For the brave pill-poppers (I mean, traders), riding this breakout could be more thrilling than reading the side effects on a medication leaflet. But remember, chasing stocks can be as dangerous as self-diagnosing on the internet!
Potential Targets:
🎯 Short-term: ₹820 (As ambitious as promising to exercise more)
🎯 Mid-term: ₹850 (Reaching for the stars, or at least the top shelf of the medicine cabinet)
IV. Risks:
If this breakout fails, the stock could drop faster than your New Year's resolution to eat healthier. Keep an eye on overall market health and be ready to take your profits before they expire like old medication.
V. Final Thoughts:
Suven Pharmaceuticals has finally broken out of its consolidation, potentially setting the stage for a rally that could cure your portfolio's ailments. Will it continue to climb, or suffer from nasty side effects? Only time will tell, but one thing's for sure – this stock is more exciting than reading the fine print on a prescription label!
Disclaimer: This analysis is about as reliable as WebMD's symptom checker. Always do your own research and consult a financial advisor before making investment decisions. Happy trading, and may your profits be as plentiful as the pills in a pharmacy! 💊🚀
MARKSANS PHARMA is in Wave 3 after Multi-Year Breakout!!Analysis Date: June 24, 2024
Marksans Pharma Stock Analysis:
General Trend:
The stock was in range for years, the previous monthly high for Marksans Pharma was Rs. 115 in August 2015. According to Elliott Wave theory, this marked the completion of Wave 1, followed by a correction and completion of Wave 2 on March 2020 and entered Wave 3.
A breakout above the previous monthly high of Rs. 115.10 was recorded in July 2023. In August, September, and October 2023, the price retested the previous high and broke out again in November, accompanied by good volume.
Entry and Exit Points:
As per ichimoku the stock still in bull mode in monthly time frame and good accumulation last few months between 140-180.
Long-term Perspective: The accumulation price range is a good area to buy the stock, with a stop loss set at Rs. 110 (monthly candle close not spike).
Short-term Perspective: Fresh buyers can enter at CMP 162 and keep averaging till near the bottom of the accumulation zone and exit near the high of the range or hold or for two supply zones till 270. The stop loss will be1 hour candle close below RS. 135.
Expected Target:
Marksans Pharma is expected to hit supply zone 1 and 2 marked in the chart, once it breaks out of the accumulation zone. This target is derived based on the application of Fibonacci extension.
Disclaimer: We are not SEBI registered. The content presented here is based on our personal opinions. Conduct your own research and consult with a qualified financial advisor before making any investment decisions.